<DOC>
	<DOCNO>NCT00060944</DOCNO>
	<brief_summary>The purpose study test safety effectiveness investigational chemotherapy agent patient type advance cancer refer liposarcoma leiomyosarcoma .</brief_summary>
	<brief_title>A Study Assess Treatment With 2 Different Dosing Schedules Trabectidin Administered Patients With Advanced Cancer</brief_title>
	<detailed_description>This open-label ( patient know name study drug receive ) , randomize ( patient assign chance receive 1 2 treatment schedule trabectidin ) study design examine survival , safety , pharmacokinetics ( blood level ) trabectedin administer patient 2 type cancer ( Liposarcoma Leiomyosarcoma ) receive treatment anti-cancer therapy ( Anthracycline and/or Ifosfamide ) . Trabectedin ( also refer Yondelis ) drug develop treat patient cancer . Yondelis administer intravenously ( i.v . ) via central catheter ( tube ) central vein week ( 0.58 mg/m2 3-hour infusion Days 1 , 8 , 15 28-day treatment cycle ) every 3 week ( 1.5 mg/m2 administer 24-hour infusion Day 1 every 21-day treatment cycle ) disease progression . Patients arm pretreated 20 mg dexamethasone i.v . 30 minute prior infusion .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Have advance liposarcoma leiomyosarcoma metastasize ( spread ) Have pathology specimen available centralize review Have progressive relapse ( reappearance ) disease , receive treatment anthracycline and/or ifosfamide enrollment study , least one measurable tumor lesion Have adequate bone marrow , liver kidney function Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Previous exposure Yondelis i.v . formulation , ET743 ( ecteinascidin ) Cancer metastasize ( spread ) central nervous system Active viral hepatitis chronic liver disease Unstable cardiac ( heart ) condition include congestive heart failure angina pectoris ( heart pain ) , myocardial infarction ( heart attack ) within 1 year enrollment History another neoplastic ( malignant nonmalignant tumor ) disease ( except basal cell carcinoma cervical carcinoma adequately treat ) , unless remission 5 year enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>ET-743</keyword>
	<keyword>Ecteinascidin</keyword>
	<keyword>Anthracycline</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignant</keyword>
	<keyword>Metastatic</keyword>
</DOC>